{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"16.5","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"ORR is defined as the percentage of patients whose tumors have a complete or partial response to treatment among eligible and treated patients. Objective response rate is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. For each treatment arm, 90% two-sided binomial exact confidence interval will be calculated for ORR.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nTrastuzumab Emtansine: Given IV","id":"OG000","title":"Treatment (Trastuzumab Emtansine)"}],"paramType":"NUMBER","populationDescription":"Patients who were eligible and received protocol treatment","reportingStatus":"POSTED","timeFrame":"Tumor assessments occurred at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration","title":"Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}